Diferencia entre revisiones de «Cefuroxime»
(Remove disease-specific dosing covered by dynamic SMW tables) |
(Remove disease-specific entries now covered by AntibioticDose (4 sections)) |
||
| Línea 7: | Línea 7: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===Skin infection=== | ===Skin infection=== | ||
*200 mg PO bid x10 days | *200 mg PO bid x10 days | ||
| Línea 28: | Línea 24: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
Revisión del 11:08 20 mar 2026
General
- Type: 3rd generation cephalosporin
- Dosage Forms: tablet
- Dosage Strengths: 200, 400mg
- Routes of Administration: PO
- Common Trade Names: Spectracef
Adult Dosing
Skin infection
- 200 mg PO bid x10 days
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Lyme disease | 500mg PO BID x 20 days | Early Lyme disease, alternative |
| Neisseria gonorrhoeae | 1000mg PO x 1 | Uncomplicated urethral/cervical/rectal infection, alternative regimen |
| Pharyngitis | 250mg PO bid x10 days | Pharyngitis/Tonsillitis, streptococcal |
| Pneumonia (main) | 500 mg BID | Outpatient, Unhealthy |
| Sinusitis | 250mg PO BID x 10 days | Alternative, not recommended per IDSA guidelines |
Pediatric Dosing
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Acute otitis media | 15mg/kg PO BID x7-10 days | Prior Month Treatment |
| Lyme disease | 30mg/kg/day PO divided BID x 20 days (max 500mg/dose) | Early Lyme disease, alternative, >13yo |
| Pharyngitis | 250mg PO bid x10 days | 12+ yo, Pharyngitis/Tonsillitis, streptococcal |
| Sinusitis | 30mg/kg/day PO divided BID x 10 days (max 500mg/dose) | Alternative, not recommended per IDSA guidelines |
Special Populations
- Pregnancy Rating: B; May use during pregnancy
- Lactation: May use while breastfeeding
- Renal Dosing
- Adult
- CrCl 30-49: Max 200mg bid
- CrCl <30: Max 200mg qd
- ESRD/HD: Not defined
- Pediatric
- CrCl 30-49: Max 200mg bid
- CrCl <30: Max 200mg qd
- ESRD/HD: Not defined
- Adult
- Hepatic Dosing
- Adult
- Child-Pugh Class A or B: No adjusment
- Child-Pugh Class C: Not defined
- Pediatric
- Child-Pugh Class A or B: No adjusment
- Child-Pugh Class C: Not defined
- Adult
Contraindications
- Allergy to class/drug
- Hypersensitivity to milk proteins
- Carnitine deficiency
- Caution:
- Hypersensitivity to PCN
- Renal impairment
- Decreased muscle mass
- Recent abx-associated colitis
Adverse Reactions
Serious
- Anaphylaxis
- Serum-sickness like reaction
- Stevens-Johnson syndrome
- Erythema multiforme
- Toxic epidermal necrolysis
- Leukopenia
- Neutropenia
- Thrombocytopenia
- Anemia, hemolytic
- Seizure
- Nephrotoxicity
- Cholestatic jaundice
- C. difficle-associated diarrhea
- Super infection
- Carnitine deficiency (long-term use)
Common
- Diarrhea
- Nausea
- Headache
- Abdominal pain
- Candidiasis, vulvovaginal
- Dyspepsia
Pharmacology
- Half-life: 1.6h; 4.7h in severe renal impairment
- Metabolism: Minimal
- Excretion: Urine primarily
- Mechanism of Action: Bactericidal; inhibits cell wall mucopeptide synthesis
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014